Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by GAM Holding AG

GAM Holding AG trimmed its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 45.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 99,448 shares of the company's stock after selling 82,850 shares during the period. GAM Holding AG owned approximately 0.22% of Omnicell worth $3,742,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Avory & Company LLC increased its holdings in shares of Omnicell by 22.7% during the third quarter. Avory & Company LLC now owns 153,776 shares of the company's stock valued at $6,926,000 after purchasing an additional 28,416 shares during the period. Vanguard Group Inc. increased its holdings in shares of Omnicell by 15.1% during the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company's stock valued at $231,374,000 after purchasing an additional 674,824 shares during the period. Pacer Advisors Inc. increased its holdings in shares of Omnicell by 321,488.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company's stock valued at $39,814,000 after purchasing an additional 1,057,698 shares during the period. Public Sector Pension Investment Board acquired a new position in Omnicell during the third quarter worth about $2,517,000. Finally, Ontario Teachers Pension Plan Board acquired a new position in Omnicell during the third quarter worth about $984,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on OMCL shares. Benchmark lowered their target price on Omnicell from $42.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, February 9th. Wells Fargo & Company lowered their target price on Omnicell from $28.00 to $26.00 and set an "equal weight" rating on the stock in a report on Friday, February 9th. Finally, Barclays started coverage on Omnicell in a report on Wednesday, January 3rd. They set an "underweight" rating and a $33.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $42.20.

Omnicell Trading Down 0.6 %

NASDAQ OMCL traded down $0.18 on Wednesday, hitting $27.57. 285,263 shares of the company were exchanged, compared to its average volume of 579,442. The company's 50 day moving average price is $28.99 and its 200-day moving average price is $34.63. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. The firm has a market capitalization of $1.27 billion, a P/E ratio of -61.67 and a beta of 0.76. Omnicell, Inc. has a twelve month low of $25.69 and a twelve month high of $77.14.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The company had revenue of $258.85 million for the quarter, compared to the consensus estimate of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. Analysts predict that Omnicell, Inc. will post 0.1 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.